Gut-derived metabolites drive Th17 cell pathogenicity in Multiple Sclerosis
The gut-brain axis is an emerging factor in promoting multiple sclerosis (MS). However, the underlying mechanisms and strategies to target this axis are not established. Here, we investigated how the gut environment influences myelin-specific Th17 cell pathogenicity. We used the adoptive Th17 cell transfer experimental autoimmune encephalomyelitis (EAE) model and antibiotic treatment to modulate the intestinal microbiome. We observed a reduced pathogenic Th17 cell signature in the colon of antibiotics-treated mice. Treatment with fecal filtrates enhanced myelin-specific Th17 cell encephalitogenic properties both in vitro and in vivo. Feces metabolomic profiling identified altered tryptophan-derived metabolites, including indole-3-carboxylate (I3CA). Oral I3CA supplementation accelerated EAE development and I3CA concentration in blood samples from persons with MS (PwMS) was associated with increased disease severity mirrored by increased serum neurofilament light chain levels. Altogether, our study shows that microbiota-derived metabolites play a key role in the intestine during neuroinflammation, offering potential therapeutic insights for PwMS. Overall design: Comparative gene expression profiling analysis of RNA-seq data of colonic lamina propria lymphocytes isolated from wild-type mice (n? = 4-6) four days after the adoptive transfer of pathogenic Th17 cells for EAE induction. Cells were FACS sorted based on viable cells and their expression of CD45.1+ CD45.2+, which characterizes the population of injected myelin-specific Th17 cells.